Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einste...
Saved in:
Main Authors: | Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-02-01
|
Series: | Journal of Hepatocellular Carcinoma |
Subjects: | |
Online Access: | https://www.dovepress.com/tolerability-and-effectiveness-of-regorafenib-treatment-in-patients-wi-peer-reviewed-fulltext-article-JHC |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Electric Fields on the Mechanical Mechanism of Regorafenib–VEGFR2 Interaction to Enhance Inhibition of Hepatocellular Carcinoma
by: Yichen Tian, et al.
Published: (2025-01-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
(−)-Epigallocatechin-3-Gallate and Quercetin Inhibit Quiescin Sulfhydryl Oxidase 1 Secretion from Hepatocellular Carcinoma Cells
by: Lumin Yang, et al.
Published: (2025-01-01) -
Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01) -
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
by: Yirui Zhai, et al.
Published: (2025-03-01)